{"id":"W4213174616","doi":"10.1200/jco.2022.40.6_suppl.tps221","title":"Talapro-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"Astellas Pharma US; Pfizer","keywords":"Enzalutamide; Medicine; Olaparib; PARP inhibitor; Prostate cancer; Internal medicine; Oncology; Placebo; Androgen receptor; Cancer; Poly ADP ribose polymerase; Pathology; Genetics; Biology; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001979301,0.002401163,0.002918324,0.0005689521,0.0005657562,0.001473309,0.001418481,0.002505174,0.008637381],"category_scores_gemma":[0.001579249,0.0009089537,0.002260463,0.0004651608,0.001453742,0.001703962,0.000473304,0.004496647,0.001618442],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009484558,"about_ca_system_score_gemma":0.0016735,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001258324,"about_ca_topic_score_gemma":0.003613512,"domain_scores_codex":[0.9994777,0.0002517317,0.00002708695,0.0001006502,0.00004087703,0.0001020457],"domain_scores_gemma":[0.99905,0.0002106261,0.0001914742,0.00006190003,0.00006635067,0.0004196949],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9702048,0.01420261,0.0002881288,0.0004430517,0.0007222542,0.00004690708,0.00005046996,0.0004070248,0.003899225,0.000132636,0.001065769,0.008537067],"study_design_scores_gemma":[0.928615,0.06916746,0.0006455113,0.00001530761,0.0002521395,0.00002749256,0.00001851101,0.0003866906,0.0002907468,0.0001467501,0.000417691,0.00001675031],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9745722,0.004643824,0.001371687,0.001619018,0.001192769,0.009960121,0.002748569,0.0004342973,0.003457507],"genre_scores_gemma":[0.9698014,0.003210315,0.003028424,0.003521923,0.0006929634,0.01059411,0.002489084,0.00008075644,0.006581231],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008637381,"threshold_uncertainty_score":0.0288949,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1570769971723807,"score_gpt":0.4840448733343991,"score_spread":0.3269678761620184,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}